Menarini's Enantyum Has "Higher Analgesic Effect Than Other NSAIDs"

13 January 1997

According to clinical research conducted on dental pain, dysmenorrheaand osteoarthritis of the knee, dexketoprofen trometamol shows a higher analgesic effect than other non-steroidal anti-inflammatories. The pharmacokinetic behavior of the enantiomer DT involves, from a therapeutic perspective, a faster onset of the analgesic effect than other NSAIDS, says the drug's developer, Laboratorios Menarini, the Spanish subsidiary of Italy's Menarini group.

In a report on the Chirality and Analgesia International Symposium held in New York by the journal Drugs (December 1996), it is confirmed that the composition of this active element causes it to dissolve quickly in the stomach, guaranteeing a fast action. Moreover, having a reduced contact time with gastric mucosa, it minimizes the undesirable gastrointestinal effects so common in other NSAIDS.

DT, now marketed in Spain as Enantyum by Menarini and Quiralam by Eli Lilly, is the result of a five-year development program at Menarini's R&D center in Barcelona, Spain. From its launch in June 1996 to November, sales reached 529,820 units. Sales of the presentation in 20 tablets of 12.5mg reached 177,484 units and those of 20 tablets of 25mg were 136,821, the firm notes.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight